NanoViricides CEO to Present at the 18th Annual BIOCEO & Investor Conference on February 8, 2016 and at the Disruptive Growth and Healthcare Conference on February 11, 2016, both in New York City
SHELTON, CONNECTICUT -- February 08, 2016 -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a nanomedicine company developing anti-viral drugs, reported that its CEO, Eugene Seymour, MD, MPH, will present information about the company's programs at the BIOCEO conference today at 5:30PM at the Waldorf-Astoria Hotel in New York City.
This presentation will be in the Windsor Room at 5:30PM EST. Registered attendees can request a one on one meeting through the conference website.
In addition, Dr. Seymour will be presenting at the Disruptive Growth and Healthcare Conference being held on February 11th, 2016, at the Convene Conference Center located at 730 Third Ave in New York City.
The latter presentation will be given between 08:30 to 08:55 AM in Track 3 - Nolita Hub. Registered attendees can request a one on one meeting through the conference website.
Dr. Seymour will review the events of the past year and discuss previously announced events.
(www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to
dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV,
oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could
differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other
written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and
unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially
affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these
forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these
forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ
materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and
elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory
authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of
principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and
obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and
market acceptance of our products.
FDA refers to US Food and Drug Administration. EMA refers to the European Union’s office of European Medical Agency.
Anil R. Diwan